文献速递淋巴瘤

抗体阻断PSGL-1免疫检查点增强T细胞对B细胞淋巴瘤的应答

Antibody blockade of the PSGL-1 immune checkpoint enhances T-cell responses to B-cell lymphoma.
PubMed 文献 · Leukemia · 2024-10-25

研究探讨靶向PSGL-1抗体在B细胞淋巴瘤中的免疫治疗潜力。体外同种异体共培养中抗人PSGL-1抗体增强T细胞活化和效应细胞因子产生,原代淋巴瘤细胞悬液体外处理增加自体淋巴瘤浸润T细胞活化;A20同基因小鼠模型中PSGL-1抗体显著减缓肿瘤发展并降低终点肿瘤负荷,伴CD4+和CD8+ T细胞浸润增加、调节性T细胞浸润减少;抗PSGL-1给药还增强先前转移至Eμ-Myc淋巴瘤小鼠的CAR T细胞扩增并改善疾病控制。结果提示PSGL-1抗体阻断增强T细胞抗B细胞淋巴瘤活性,可能是一种潜在的新型免疫治疗途径。

要点

  • 抗人PSGL-1抗体在体外共培养中增强T细胞活化和效应细胞因子产生。
  • PSGL-1抗体体外处理原代淋巴瘤细胞增加自体淋巴瘤浸润T细胞活化。
  • A20小鼠模型中PSGL-1抗体减缓肿瘤发展、降低终点肿瘤负荷并调节T细胞浸润。

核心结论

  • PSGL-1抗体阻断增强T细胞对B细胞淋巴瘤的活性,提示可能是一种潜在的新型免疫治疗途径。

研究设计与样本

  • 研究采用同种异体共培养系统、原代淋巴瘤细胞悬液体外处理、A20同基因B细胞淋巴瘤小鼠模型及Eμ-Myc淋巴瘤小鼠过继转移CAR T细胞模型。

主要发现

  • 靶向人PSGL-1的抗体干预增强T细胞活化和效应细胞因子产生。
  • 原代淋巴瘤细胞悬液体外经PSGL-1抗体处理增加自体淋巴瘤浸润T细胞活化。
  • A20小鼠模型中PSGL-1抗体治疗显著减缓肿瘤发展并降低终点肿瘤负荷。
  • 抗肿瘤效应伴随CD4+和CD8+ T细胞肿瘤浸润增加及调节性T细胞浸润减少。
  • 抗PSGL-1给药增强先前转移至Eμ-Myc淋巴瘤小鼠的CAR T细胞扩增并改善疾病控制。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Despite advancements in cancer immunotherapy, most lymphomas remain unresponsive to checkpoint inhibitors. P-selectin glycoprotein ligand-1 (PSGL-1), recently identified as a promoter of T-cell exhaustion in murine melanoma models, has emerged as a novel immune checkpoint protein and promising immunotherapeutic target. In this study, we investigated the potential of PSGL-1 antibody targeting in B-cell lymphoma. Using allogeneic co-culture systems, we demonstrated that targeted antibody interventions against human PSGL-1 enhanced T-cell activation and effector cytokine production in response to lymphoma cells. Moreover, in vitro treatment of primary lymphoma cell suspensions with PSGL-1 antibody resulted in increased activation of autologous lymphoma-infiltrating T cells. Using the A20 syngeneic B-cell lymphoma mouse model, we found that PSGL-1 antibody treatment significantly slowed tumor development and reduced the endpoint tumor burden. This antitumoral effect was accompanied by augmented tumor infiltration of CD4+ and CD8+ T cells and reduced infiltration of regulatory T cells. Finally, anti-PSGL-1 administration enhanced the expansion of CAR T cells previously transferred to mice bearing the aggressive Eμ-Myc lymphoma cells and improved disease control. These results demonstrate that PSGL-1 antibody blockade bolsters T-cell activity against B-cell lymphoma, suggesting a potential novel immunotherapeutic approach for treating these malignancies.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Pereira JL, Arede L, Ferreira F, et al. Antibody blockade of the PSGL-1 immune checkpoint enhances T-cell responses to B-cell lymphoma. Leukemia. 2024. PMID: 39455852. doi:10.1038/s41375-024-02446-w

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。